Polyganics has initiated a clinical trial to assess its Actiseal liver and pancreas sealant patch for hepato-pancreato-biliary (HPB) surgery. Actiseal received Breakthrough Device Designation in 2018
Device Transactions During the first quarter of 2016, device companies raised an aggregate $1.8 billion in financing, a 50% increase over last quarter's $1.2 billion. Debt was the top financing vehicl
Get your product into market, grow sales, reach profitability. These are the key goals of any start-up but for biomaterials specialist Polyganics BV , being able to tick all those boxes was not eno